Status of Implantable VADs
|
|
- Clare Arnold
- 5 years ago
- Views:
Transcription
1 Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions
2 Conflict of Interest Statement No Financial Interests Investigator Thoratec: Heartmate 2 LVAD Heartware: HVAD LVAD Abiomed : Abiocor TAH
3 Status of Implantable VADs Current approved devices Contemporary outcomes Survival Complications GI Bleeding Thrombosis Stroke Infection Future Considerations
4 Implantable VAD
5 Indications for Implantable LVADs Bridge to Transplant (BTT) Non-reversible left heart failure Imminent risk of death Candidate for cardiac transplantation Destination Therapy (DT) NYHA Class IIIB or IV heart failure Optimal medical therapy 45 of last 60 days Not candidate for cardiac transplantation
6 Worldwide Clinical Experience > 10,000 Patients Implanted Pilot Trial n=53 Pivotal Trial Commercial n=1315* Experience *as treated n>9000 (+114 XVEs) Bridge to Transplant n=490 BTT Approvals CE Mark: Nov FDA: Apr Health Canada: May 2009 Destination Therapy n=825 DT Approvals CE Mark: Nov FDA: Jan Health Canada: Nov 2010 On file with Thoratec As of Apr 2012
7 Worldwide Clinical Experience* More than 10,000 patients worldwide have now been implanted with the HeartMate II LVAS. Patients supported 1 year: 3771 Patients supported 2 years: 1528 Patients supported 3 years: 552 Patients supported 4 years: 194 Patients supported 5 years: 62 Patients supported 6 years: 16 Patients supported 7 years: 1 On file with Thoratec As of Apr 2012 *Based on clinical trial and device tracking data
8 Heartmate 2: BTT Experience Survival Percent Implant dates n 30 d 6 Mo 12 mo 50 a Apr 08 - Oct % 89% 85% b Apr 08 - Aug % 90% 85% 40 c Mar 07 - Apr % 86% 80% d Mar 05 - Mar % 82% 73% e Mar 05 - May % 75% 68% a John et al STS 2011 b Starling et al JACC (in press) d Pagani et al JACC 2009 e Miller et al NEJM Months Post-Trial a Post-Approval Study b Late Trial c Early-mid Trial d Early Trial e
9 INTERMACS Profiles Starling, Naka, Boyle, et al. JACC. 2011;57:19.
10 Outcomes Based on INTERMACS Profile Length of Stay Post-VAD Actuarial Survival Post-VAD Less acutely ill, ambulatory patients in INTERMACS profiles 4 7 had better survival and reduced length of stay compared to patients who were more accurately ill in profiles 1 3. Group 1: INTERMACS 1 Group 2: INTERMACS 2 3 Group 3: INTERMACS 4 7 Boyle, Ascheim, Russo, et al. JHLT. 2011;30:4.
11 . End-Organ Function Data Renal Function BUN (mg/dl) Creatinine (mg/dl) VAD Day Baseline Values: Above Normal Baseline Values: Normal All Pts with abnormal renal function group demonstrated significant improvements (p<0.0001) over the period of support. Russell SD, Rogers JG, Milano CA, et al, Circulation, 2009;120:
12 End-Organ Function Data Hepatic Function Total Bilirubin (mg/dl) Baseline Values: Above Normal 1. 0 Baseline Values: Normal 0. 0 All AST (U/L) ALT (U/L) V A D D a y Pts with abnormal hepatic function group demonstrated significant improvements (p<0.001) over the period of support. Russell SD, Rogers JG, Milano CA, et al, Circulation, 2009;120:
13 500 HM2 DT Trial CAP: Functional Class Improvements 6-Minute Walk Test and NYHA Functional Class I & II 6MWD NYHA Class I or II 400 EarlyTrial (N=133) Distance (m meters) Mid Trial (N=281) P < over time P = between groups P = interaction Pts Tested Months Pts Tested: Park, S, et al Circ Heart Fail
14 HeartMate Functional II demonstrated Capacity and clinically Quality of meaningful Life Data improvements across each of the five measures assessed Clinically Meaningful during Measure the HeartMate II Pivotal Measure Focus Trial. HM II Data Change Change Six Minute Walk Test Functional Capacity 39-m m NYHA Functional Assessment Functional Capacity 1 NYHA Improvement 80% 2 NYHA Improvements Metabolic Equivalent Task Score (METs) Functional Capacity 1 MET Improvement 60% 1 MET Improvement Minnesota Living with Heart Failure Quality of Life 5 points points Kansas City Cardiomyopathy Questionnaire Quality of Life 5 points points 1 Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346: Rector TS, Cohn JN., Am Heart J 1992;124: Rector TS, Kubo SH, Cohn JN. Am J Cardiol 1993;71: Spertus J, Peterson E, Conard MW, et al. Am Heart J 2005;150: Majani G, Giardini A, Opasich C, et alj Card Fail 2005;11: Rogers JG, Aaronson KD, Boyle AJ et al, JACC, 2010;55:
15 Patients demonstrated neurocognitive improvement in each Neurocognitive of the five domains Function over Data the two year follow-up period with no decline seen during any interval. p-values Domain Test 3 mo 6 mo 12 mo 24 mo (1) Visual-Spatial Perception (2) Memory Auditory Clock Drawing WAIS-III Block Design < WMS-III LM <0.001 <0.001 <0.001 <0.001 WMS-III LM Delay <0.001 <0.001 <0.001 <0.001 (2) Memory Visual WMS-III VR <0.001 <0.001 < WMS VR Delay <0.001 <0.001 <0.001 <0.001 (3) Executive Function WAIS-III Digit Symbol <0.001 < Trail Making B < (4) Language Boston Naming (abbrev) <0.001 <0.001 (5) Processing Speed Trail Making A < Statistically Significant Improvement Petrucci R, Russell S, Gallagher C, et. al., ISHLT 2010.
16 HeartMateII Adverse Events Post-approval study pts experienced a reduced or similar rate of adverse events in a broader patient care environment compared to clinical trial patients. No pump replacements through the first 6 mos of support in the post-approval study group. Starling, Naka, Boyle, et al. JACC. 2011;57: PaganiFD, Miller LW, Russell SD.. J Am CollCardiol. 2009;54:
17 HM II Risk Score Study Cohorts Patients undergoing HeartMateII implant enrolled into the HeartMateII Bridge-to-Transplant (N=489) 1,2 and Destination Therapy (N=633) 3 trials were included (Total N=1,122). Multivariable analyses were performed to identify the risk factors of death following LVAD implantation. Patients were prospectively and randomly assigned to either the derivation cohort or to the validation cohort. Cowger J, Sundareswaran K, Rogers J, et al. ISHLT Miller L, Pagani F, et al. N Engl J Med. 2007;357: Pagani F, Miller L, et al. JACC. 2009;54: Slaughter M, Milano C, Rogers J, et al. N Engl J Med. 2009;361:
18 Risk Stratification in HeartMate II Patients Comparison of Derivation and Validation Cohorts Cowger J, Sundareswaran K, Rogers J, et al. ISHLT 2011.
19 Multivariate Predictors* of Death Post LVAD Cowger J, Sundareswaran K, Rogers J, et al. ISHLT 2011.
20 Bleeding, Stroke, Thrombosis HM2 Outpatients Russell SD, Boyle A, Sun B, et al. ISHLT 2011.
21 Female Gender Only Independent Risk Factor for Stroke and Pump Thrombosis Females were twice as likely to experience a stroke or pump thrombosis event. Russell SD, Boyle A, Sun B, et al. ISHLT 2011.
22 Impact of Infection on Stroke and Thrombosis During a ±14 day window around an infection event patients were: 4 times more likely to experience a hemorrhagic stroke event 8 times more likely to experience an ischemic stroke event 9 times more likely to experience a pump thrombosis event Russell SD, Boyle A, Sun B, et al. ISHLT 2011.
23 Driveline Infections
24 Velour Versus Silicone Skin Interface Velour N=16 Silicone N=16 Mean Age (years) Gender (M/F) 14/2 13/3 Indication (BTT/BTC/DT) 11/1/4 13/1/2 Ledford ID, Miller DV, Mason NO, et al. ISHLT 2011.
25 Histology Velour exhibits more dermal inflammation and an irregular shaped stratum corneum. Silicone is smooth and regular, and shows less inflammation. Ledford ID, Miller DV, Mason NO, et al. ISHLT 2011.
26 Contemporary DT Results Park SJ. AHA Scientific Sessions, November Slaughter M, Milano C, Rogers J, et al. N EnglJ Med. 2009;361:
27 Contemporary DT Results Park SJ. AHA Scientific Sessions, November 2010.
28 Contemporary DT Results The CAP results show a decrease in major adverse events. Park SJ. AHA Scientific Sessions, November 2010.
29 Heartware HVAD BTT and CAP 241 ptsthru 1/15/11
30 European Assoc Cardiothoracic Surgery Oct 2011
31 HM2 64 % Intermacs1 & 2 European Assoc Cardiothoracic Surgery Oct 2011
32 HM with velour and 0.0 with silicone HM2 3% RVAD European Assoc Cardiothoracic Surgery Oct 2011
33 HM events HM events European Assoc Cardiothoracic Surgery Oct 2011
34 European Assoc Cardiothoracic Surgery Oct 2011
35 European Assoc Cardiothoracic Surgery Oct 2011
36 European Assoc Cardiothoracic Surgery Oct 2011
37 Future Considerations
38 Non Sternotomy LVAD Insertion
39 Non Sternotomy LVAD Insertion
40 Heartware
41 Heartware Miniaturization May Lead to Multiple VAD Configurations Flow 2-10 L/min 1-8 L/min 1 8 L/min 1-8 L/min Size 58 mm tall 46 mm tall 46 mm tall with 8cm cannula mm length Impeller wide blade centrifugal wide blade axial wide blade axial wide blade axial RPM 1,800 4,000 12,000 24,000 12,000 24,000 12,000 24,000
42 Heartmate
43 Circulite
44 44
45 2012 ISHLT Annual Meeting Prague Czech Republic B. Meyns, F. Rega, M. Strueber, A. Barbone, E. Vitaliand D. Burkhoff "A New Treatment Option for INTERMACS Profile 4, 5 and 6 Patients with the Circulite Synergy System 50 patients, 28 hemodynamic data Longest pt2.6 yrs, many over 1 yr Last 13 pa ents have significantly rate of overall SAE s (events per patient-years). No strokes or other episodes of neurologic dysfunction
46 MinVasc W Cohn, Texas Heart Inst.
47
48 Driveline Infections
49 Transcutaneous Energy Transmission Systems (TETS)
50 Magnetically Coupled Resonators Magnetic Resonance to wirelessly transfer energy Based on work of Nikola Tesla early 20 th century Presented STS 2012
51 New TAH = Creative VAD Adaptation
52 Thank you!
Mechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationNone. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
More informationDo we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine
Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationFurther devices to treat heart failure
Postgraduate Course Heart Failure Further devices to treat heart failure Pr. Matthias Kirsch Department of Cardiac Surgery Centre Hospitalo-Universitaire Vaudois Université de Lausanne e-mail: matthias.kirsch@chuv.ch
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationPediatric Mechanical Circulatory Support - What to Use
Pediatric Mechanical Circulatory Support - What to Use Ronald K. Woods, MD, PhD Associate Professor Medical College of Wisconsin Pediatric Cardiothoracic Surgery Children s Hospital of Wisconsin Disclosure
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationNew ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010
New ventricular assist devices FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010 The real world of CHF Prevalence 1-3% in europe, in the age of 70-80 years up to 10-20%
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationHeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationComplications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel
Complications of Left Ventricular Assist Device Chronic Support. Dr. Tal Hasin RMC, Beilinson, Petach-Tiqva, Israel No disclosures Probability of survival Survival (%) Survival with LVAD Destination Bridge
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationContinuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD, Nicholas G. Smedira, MD, Randall Starling, MD, MPH,
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationPredicting Survival in Patients Receiving Continuous Flow Left Ventricular Assist Devices
Journal of the American College of Cardiology Vol. 61, No. 3, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.055
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More informationEnd-Stage Heart Failure Care: Advances in Technology and Patient Survival
End-Stage Heart Failure Care: Advances in Technology and Patient Survival Colleen Ciampa, RN, MN, CNS, NP-C St. Vincent Hospital Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Program
More informationEnd Stage Heart Failure - Time to Bring the Hammer Down
End Stage Heart Failure - Time to Bring the Hammer Down Eric R. Skipper, MD, FACS Chief, Adult Cardiovascular Surgery Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support 2 3
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationReadmissions: an unavoidable nemesis
Readmissions: an unavoidable nemesis This presentation was presented at the Thoratec Corporation Economic Summit held on September 30-October 2 in La Jolla, CA. Please note that this presentation and content
More informationMechanical Circulatory Support for Unstable Heart Failure
Mechanical Circulatory Support for Unstable Heart Failure Michael A. Acker, MD William Measey Professor of Surgery Chief of Cardiovascular Surgery University of Pennsylvania Health System O.H. Frazier,
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationMechanical Circulatory Support (MCS) in 2017: What is New and Different?
Mechanical Circulatory Support (MCS) in 2017: What is New and Different? Rick Thompson, MD Photo Courtesy of St. Jude, Inc Disclosures Together+Clinic Co-Founder CR Bard Consultant MedlaunchSolutions Co-Founder
More informationHow to Develop a Comprehensive Ventricular Assist Device Program
How to Develop a Comprehensive Ventricular Assist Device Program Rodrigo V. González, MD, MS Sección de Cirugía Cardiovascular División de Cirugía Facultad de Medicina Pontificia Universidad Católica de
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More information3/1/2017. Chronic Mechanical Support for Heart Failure. Heart Failure is a major driver of morbidity and mortality in the US 1-7
Chronic Mechanical Support for Heart Failure Margarita Camacho MD, FACS Surgical Director Cardiac Transplant and Mechanical Assist Device Program RWJ/Barnabas Health Heart Centers at Newark Beth Israel
More informationEMS and Nursing Considerations in VAD Patient Care
EMS and Nursing Considerations in VAD Patient Care B R I T T A N Y B U T Z L E R B S N R N V A D C O O R D I N A T O R F R O E D T E R T A N D T H E M E D I C A L C O L L E G E O F W I 1 0 / 2 5 / 1 8
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES
MEDICAL POLICY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationCHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality
More informationI have nothing to disclose.
I have nothing to disclose. Right ventricular failure and need for biventricular support Friedrich Wilhelm Mohr, MD, PhD Munich, August 27, 2012 Male; date of birth: 19.07.1984 Out clinic visit 10/ 2004:
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationOutcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy
Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy Soon J. Park, MD; Carmelo A. Milano, MD; Antone J. Tatooles, MD; Joseph G. Rogers, MD; Robert M.
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationTranslating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist
Translating Device and Mechanical Support Guidelines to ACHD Research Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist Disclosures No financial disclosures May discuss off-label or investigational
More informationHeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial
http://www.jhltonline.org FEATURED ARTICLES HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial Mark S. Slaughter,
More informationLeft ventricular assist devices current state and perspectives
Review Article Left ventricular assist devices current state and perspectives Anatol Prinzing 1, Ulf Herold 1, Anna Berkefeld 2, Markus Krane 1,3, Rüdiger Lange 1,3, Bernhard Voss 1 1 Department of Cardiovascular
More informationMechanical support of the failing heart: Will heart transplantation become obsolete? Charles Lindbergh
William Pierce, MD What ever happened to the artificial heart? Mechanical support of the failing heart: Will heart transplantation become obsolete? Dan M. Meyer, MD The 20 th Annual Donald and Lois Roon
More informationDestination Therapy For Advanced Heart Failure
Destination Therapy For Advanced Heart Failure Kevin Guffey, RN Vad Coordinator Tacoma General Hospital April 28, 2012 Current HF Estimates 300 Million Population HF=2.5% of Population 6.5-7 Million Patients
More informationHeart Transplantation
Heart Transplantation Age and Outcome Mayo Clinic Richard Daly, MD Professor of Surgery Surgical Director Heart & Lung Transplantation 2014 MFMER 3346076-1 Rochester, Minnesota 2014 MFMER 3346076-2 The
More informationIntrapericardial Left Ventricular Assist Device for Advanced Heart Failure
The new england journal of medicine Original Article Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure Joseph G. Rogers, M.D., Francis D. Pagani, M.D., Ph.D., Antone J. Tatooles,
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationOutcomes in Advanced Heart Failure Patients with Left Ventricular. Assist Devices for Destination Therapy
Outcomes in Advanced Heart Failure Patients with Left Ventricular Assist Devices for Destination Therapy Park et al: HeartMate II for Destination Therapy Soon J. Park, MD, Carmelo A. Milano, MD, Antone
More informationLEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus
LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus OBJECTIVES Review the most common LVAD-related complications.
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationMechanical Circulatory Support for the Failing Heart Progress, Pitfalls and Promises
Heart, Lung and Circulation (2015) 24, 527 531 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2015.02.004 EDITORIAL Mechanical Circulatory Support for the Failing Heart Progress, Pitfalls and Promises
More informationMulticenter Evaluation of an Intrapericardial Left Ventricular Assist System
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.040
More informationMultiple case reports of successful use, with only one case report of intra device thrombotic event
rfviia in VAD Patients Limited data exist regarding safety Multiple factors increase pro thrombotic potential Multiple case reports of successful use, with only one case report of intra device thrombotic
More informationMEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationAcute Circulatory Support Should We or Shouldn t We?
Acute Circulatory Support Should We or Shouldn t We? Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationLVADs as Destination Therapy: When Best Practice Criteria Meets the Real World
LVADs as Destination Therapy: When Best Practice Criteria Meets the Real World Farooq Sheikh, M.D., FACC Advanced Heart Failure Program MedStar Washington Hospital Center Disclosure I have no relevant
More informationLeft Ventricular Assist Devices: Physiology, Complications and Emergencies
Left Ventricular Assist Devices: Physiology, Complications and Emergencies Sara Kalantari, MD Assistant Professor of Medicine, Heart Transplant & Mechanical Circulatory Support Program University of Chicago
More informationHFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy
HFA- ESC criteria for Advanced HF and US Requirements for Destination Therapy ESC- HFA criteria for Adv-HF Severe symptoms of HF (NYHA class III or IV) with episodes of fluid retention and/or peripheral
More informationReadmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital
Readmissions After Ventricular Assist Device: Etiologies, Patterns, and Days Out of Hospital Stephen J. Forest, MD, Ricardo Bello, MD, PhD, Patricia Friedmann, MS, Danielle Casazza, RN, Cecilia Nucci,
More informationVentricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study
Ventricular Assist Device Implant in the Elderly Is Associated With Increased, but Respectable Risk: A Multi-Institutional Study Pavan Atluri, MD, Andrew B. Goldstone, MD, Dale M. Kobrin, BA, Jeffrey E.
More informationAge and Outcome After Continuous-Flow Left Ventricular Assist Device Implantation as Bridge to Transplantation
Age and Outcome After Continuous-Flow Left Ventricular Assist Device Implantation as Bridge to Transplantation Sigrid E. Sandner, MD, a Daniel Zimpfer, MD, a Philipp Zrunek, a Angela Rajek, MD, b Heinrich
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationCandidate Selection for Long Term VAD
6th Saudi Heart Failure Symposium Riyadh - December 9, 2017 Candidate Selection for Long Term VAD AMMAR CHAUDHARY, MBCHB, FRCPC Consultant Cardiologist Advanced Heart Failure Department of Cardiology King
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationOriginally indicated as a bridge to transplantation, left
ETHICS, PUBLIC POLICY AND MEDICAL ECONOMICS A Call for Guidance in the Use of Left Ventricular Assist Devices in Older Adults Caroline A. Vitale, MD, * Rashmi Chandekar, MD, Phillip E. Rodgers, MD, Francis
More informationSixth INTERMACS annual report: A 10,000-patient database
http://www.jhltonline.org INTERMACS ANNUAL FEATURE Sixth INTERMACS annu report: A 10,000-patient database James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationThe Centers for Medicare & Medicaid Services (CMS) proposes the following changes to the current national coverage determination (NCD).
Proposed Decision Memo for Ventricular Assist Devices for Bridge-to-Transplant and Destination Therapy (CAG-00432R) Decision Summary The Centers for Medicare & Medicaid Services (CMS) proposes the following
More informationHISTORICAL PERSPECTIVES OF MECHANICAL CARDIAC ASSIST
HISTORICAL PERSPECTIVES OF MECHANICAL CARDIAC ASSIST Rohinton J. Morris, MD Chief- Cardiothoracic Surgery, Abington-Jefferson Health Systems PROGRAM Past From inception to clinical use Present Devices,
More informationRepeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint
ASAIO Journal 2017 Adult Circulatory Support Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint TERUHIKO IMAMURA,* DANIEL BURKHOFF, DANIEL RODGERS,* SIRTAZ ADATYA,*
More informationDerivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score Osama I.I. Soliman, MD, PhD, FACC,
More information1/21/2016. HeartMate II Indications for Use. Ventricular Assist Device Overview. Jon G. Echterling MSN, CCRN, FNP-BC. Learning Objectives
Ventricular Assist Device Overview Jon G. Echterling MSN, CCRN, FNP-BC February 5, 2016 Learning Objectives Identify the components and operation of the HeartMate II LVAD Describe the path blood follows
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationExtended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist Device
Journal of the American College of Cardiology Vol. 54, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.055
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2017 Origination: 12/2001 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More information